155 related articles for article (PubMed ID: 36478416)
1. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
3. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
[TBL] [Abstract][Full Text] [Related]
4. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
Nakamura T; Tateishi K; Niwa T; Matsushita Y; Tamura K; Kinoshita M; Tanaka K; Fukushima S; Takami H; Arita H; Kubo A; Shuto T; Ohno M; Miyakita Y; Kocialkowski S; Sasayama T; Hashimoto N; Maehara T; Shibui S; Ushijima T; Kawahara N; Narita Y; Ichimura K
Neuropathol Appl Neurobiol; 2016 Apr; 42(3):279-90. PubMed ID: 26111727
[TBL] [Abstract][Full Text] [Related]
5. CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.
Yonese I; Takase H; Yoshimori M; Onozawa E; Tsuzura A; Miki T; Mochizuki M; Miura O; Arai A
Eur J Haematol; 2019 Feb; 102(2):191-196. PubMed ID: 30390359
[TBL] [Abstract][Full Text] [Related]
6. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.
Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N
Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
8. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
Nagane M
Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
[TBL] [Abstract][Full Text] [Related]
9. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract][Full Text] [Related]
10. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.
Zhou Y; Liu W; Xu Z; Zhu H; Xiao D; Su W; Zeng R; Feng Y; Duan Y; Zhou J; Zhong M
Neoplasia; 2018 Oct; 20(10):1059-1069. PubMed ID: 30227305
[TBL] [Abstract][Full Text] [Related]
12. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
Yamada S; Ishida Y; Matsuno A; Yamazaki K
Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
[TBL] [Abstract][Full Text] [Related]
13. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
14. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
Cao XX; Li J; Cai H; Zhang W; Duan MH; Zhou DB
Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
[TBL] [Abstract][Full Text] [Related]
15. A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.
Tateishi K; Miyake Y; Kawazu M; Sasaki N; Nakamura T; Sasame J; Yoshii Y; Ueno T; Miyake A; Watanabe J; Matsushita Y; Shiba N; Udaka N; Ohki K; Fink AL; Tummala SS; Natsumeda M; Ikegaya N; Nishi M; Ohtake M; Miyazaki R; Suenaga J; Murata H; Aoki I; Miller JJ; Fujii Y; Ryo A; Yamanaka S; Mano H; Cahill DP; Wakimoto H; Chi AS; Batchelor TT; Nagane M; Ichimura K; Yamamoto T
Cancer Res; 2020 Dec; 80(23):5330-5343. PubMed ID: 33067267
[TBL] [Abstract][Full Text] [Related]
16. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
17. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
Sasaki N; Nagane M
No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
[TBL] [Abstract][Full Text] [Related]
18.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
19. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.
Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T
Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547
[TBL] [Abstract][Full Text] [Related]
20. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]